These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 29444257)

  • 1. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    Lo NC; Gupta R; Stanaway JD; Garrett DO; Bogoch II; Luby SP; Andrews JR
    J Infect Dis; 2018 Nov; 218(suppl_4):S232-S242. PubMed ID: 29444257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
    Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
    Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.
    Antillón M; Bilcke J; Paltiel AD; Pitzer VE
    Vaccine; 2017 Jun; 35(27):3506-3514. PubMed ID: 28527687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.
    Andrews JR; Baker S; Marks F; Alsan M; Garrett D; Gellin BG; Saha SK; Qamar FN; Yousafzai MT; Bogoch II; Antillon M; Pitzer VE; Kim JH; John J; Gauld J; Mogasale V; Ryan ET; Luby SP; Lo NC
    Lancet Infect Dis; 2019 Jan; 19(1):e26-e30. PubMed ID: 30170987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of typhoid fever transmission dynamic models and economic evaluations of vaccination.
    Watson CH; Edmunds WJ
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C42-54. PubMed ID: 25921288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study.
    Ryckman T; Karthikeyan AS; Kumar D; Cao Y; Kang G; Goldhaber-Fiebert JD; John J; Lo NC; Andrews JR
    J Infect Dis; 2021 Nov; 224(Supple 5):S612-S624. PubMed ID: 35238367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Typhoid fever vaccination strategies.
    Date KA; Bentsi-Enchill A; Marks F; Fox K
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C55-61. PubMed ID: 25902360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.
    Phillips MT; Antillon M; Bilcke J; Bar-Zeev N; Limani F; Debellut F; Pecenka C; Neuzil KM; Gordon MA; Thindwa D; Paltiel AD; Yaesoubi R; Pitzer VE
    BMC Infect Dis; 2023 Mar; 23(1):143. PubMed ID: 36890448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities for Typhoid Vaccination in India.
    Srinivasan M; Sindhu KN; John J; Kang G
    Indian Pediatr; 2019 Jun; 56(6):453-458. PubMed ID: 31278221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Burrows H; Antillón M; Gauld JS; Kim JH; Mogasale V; Ryckman T; Andrews JR; Lo NC; Pitzer VE
    Vaccine; 2023 Jan; 41(4):965-975. PubMed ID: 36586741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.
    Weyant C; Hooda Y; Munira SJ; Lo NC; Ryckman T; Tanmoy AM; Kanon N; Seidman JC; Garrett D; Saha SK; Goldhaber-Fiebert JD; Saha S; Andrews JR
    Vaccine; 2024 Apr; 42(11):2867-2876. PubMed ID: 38531727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009.
    Podda A; Saul AJ; Arora R; Bhutta Z; Sinha A; Gaind R; Singhal T; Saha S; Brooks A; Martin LB; Amdekar Y; Chitkara AJ; Shieh M; Kapur AN; Chugh TD
    J Infect Dev Ctries; 2010 Jun; 4(6):404-11. PubMed ID: 20601795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating investments in typhoid vaccines in two slums in Kolkata, India.
    Cook J; Sur D; Clemens J; Whittington D
    J Health Popul Nutr; 2009 Dec; 27(6):711-24. PubMed ID: 20099754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.
    Mogasale V; Ramani E; Park IY; Lee JS
    Hum Vaccin Immunother; 2017 Sep; 13(9):2017-2024. PubMed ID: 28604164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper.
    Laurens MB; Sirima SB; Rotrosen ET; Siribie M; Tiono A; Ouedraogo A; Liang Y; Jamka LP; Kotloff KL; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S59-S66. PubMed ID: 30845330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
    Yousafzai MT; Karim S; Qureshi S; Kazi M; Memon H; Junejo A; Khawaja Z; Ur Rehman N; Ansari MS; Ali R; Ujjan IU; Lohana HM; Memon NM; Hussain M; Nigar R; Bar-Zeev N; Qamar FN
    Lancet Glob Health; 2021 Aug; 9(8):e1154-e1162. PubMed ID: 34297962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
    Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.